• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EDIT

    Editas Medicine Inc.

    Subscribe to $EDIT
    $EDIT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio and collaboration with m BlueRock Therapeutics LP. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

    IPO Year: 2016

    Exchange: NASDAQ

    Website: editasmedicine.com

    Peers

    $ADVM
    $CRSP
    $NTLA

    Recent Analyst Ratings for Editas Medicine Inc.

    DatePrice TargetRatingAnalyst
    4/28/2025$3.00Buy
    H.C. Wainwright
    12/16/2024Neutral → Underweight
    Analyst
    12/13/2024Buy → Neutral
    Chardan Capital Markets
    12/13/2024Buy → Hold
    Truist
    12/13/2024$11.00 → $3.00Buy → Hold
    Stifel
    12/11/2024$7.00 → $4.00Overweight → Equal Weight
    Wells Fargo
    11/25/2024$13.00 → $1.00Buy → Underperform
    BofA Securities
    11/6/2024In-line → Outperform
    Evercore ISI
    11/4/2024Outperform → Mkt Perform
    Raymond James
    8/8/2024$13.00 → $15.00Neutral → Buy
    BofA Securities
    See more ratings

    Editas Medicine Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/12/24 2:30:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      11/4/24 11:57:08 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      10/17/24 1:10:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      7/10/24 6:28:34 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      4/10/24 9:37:23 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      2/14/24 8:40:25 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      2/13/24 5:04:50 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      1/24/24 2:27:13 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Editas Medicine Inc. (Amendment)

      SC 13G/A - Editas Medicine, Inc. (0001650664) (Subject)

      1/10/24 9:09:56 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Editas Medicine Inc.

      SC 13G - Editas Medicine, Inc. (0001650664) (Subject)

      8/4/23 4:17:27 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Financial Officer Parison Amy

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:29:42 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Parison Amy claimed ownership of 17,952 shares (SEC Form 3)

      3 - Editas Medicine, Inc. (0001650664) (Issuer)

      4/8/25 4:20:50 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, CHIEF FINANCIAL OFFICER Lucera Erick

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/27/25 4:41:59 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CEO O'Neill Gilmore Neil

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/27/25 4:37:39 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/27/25 4:33:48 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP, CHIEF FINANCIAL OFFICER Lucera Erick sold $7,030 worth of shares (4,109 units at $1.71), decreasing direct ownership by 4% to 112,720 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/5/25 4:44:08 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO O'Neill Gilmore Neil sold $28,452 worth of shares (16,632 units at $1.71), decreasing direct ownership by 5% to 295,474 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/5/25 4:43:12 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $4,946 worth of shares (2,891 units at $1.71), decreasing direct ownership by 4% to 70,245 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      3/5/25 4:41:55 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CEO O'Neill Gilmore Neil sold $3,361 worth of shares (1,618 units at $2.08), decreasing direct ownership by 0.52% to 312,106 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      12/5/24 4:40:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • EVP, CHIEF MEDICAL OFFICER Mei Baisong sold $1,124 worth of shares (541 units at $2.08), decreasing direct ownership by 0.40% to 133,354 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      12/5/24 4:37:25 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    Editas Medicine Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Editas Medicine with a new price target

      H.C. Wainwright initiated coverage of Editas Medicine with a rating of Buy and set a new price target of $3.00

      4/28/25 8:37:22 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Analyst

      Analyst downgraded Editas Medicine from Neutral to Underweight

      12/16/24 6:44:11 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Chardan Capital Markets

      Chardan Capital Markets downgraded Editas Medicine from Buy to Neutral

      12/13/24 8:14:41 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Truist

      Truist downgraded Editas Medicine from Buy to Hold

      12/13/24 7:37:40 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Stifel with a new price target

      Stifel downgraded Editas Medicine from Buy to Hold and set a new price target of $3.00 from $11.00 previously

      12/13/24 7:37:09 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Editas Medicine from Overweight to Equal Weight and set a new price target of $4.00 from $7.00 previously

      12/11/24 7:30:58 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by BofA Securities with a new price target

      BofA Securities downgraded Editas Medicine from Buy to Underperform and set a new price target of $1.00 from $13.00 previously

      11/25/24 7:41:18 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine upgraded by Evercore ISI

      Evercore ISI upgraded Editas Medicine from In-line to Outperform

      11/6/24 12:16:34 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine downgraded by Raymond James

      Raymond James downgraded Editas Medicine from Outperform to Mkt Perform

      11/4/24 12:17:43 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine upgraded by BofA Securities with a new price target

      BofA Securities upgraded Editas Medicine from Neutral to Buy and set a new price target of $15.00 from $13.00 previously

      8/8/24 6:59:16 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

      4 - Editas Medicine, Inc. (0001650664) (Issuer)

      5/14/24 4:17:23 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

      CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conference in May: Bank of America Global Healthcare Conference Format: Fireside ChatDate: Tuesday, May 13Time: 5:15 p.m. PTLocation: Las Vegas, NV To access

      5/5/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

      CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medicine presentations at ASGCT include: Oral presentation of in vivo preclinical data from humanized mouse and non-human primate (NHP) studies using targeted lipid nanoparticles (tLNPs) to

      4/28/25 4:31:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Chief Financial Officer Transition

      Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company, today announced Chief Financial Officer Erick J. Lucera is stepping down to pursue an external opportunity, effective March 28, 2025. Current Senior Vice President of Finance Amy Parison will succeed Mr. Lucera as Chief Financial Officer. "We are thrilled to promote Amy to the executive leadership team as our new CFO. Amy joined Editas two and a half years ago as our head of Finance, working closely with the CFO. Her track record of financia

      3/20/25 4:01:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

      On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

      3/5/25 4:05:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

      CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates on March 5 via press release and SEC filings. The Company does not plan to host quarterly financial results conference calls moving forward. Additionally, Editas Medicine management will participate in the following upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Format: Fireside ChatDate: Monday, March 3Time: 2:30 p.m. ETLocation: Boston, MA Leerink Partners

      2/24/25 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

      Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Achieved in vivo editing of liver cells in non-human primates and in vivo delivery to two additional cell types in humanized mice Anticipated 2025 milestones include: declare two in vivo development candidates, one in HSCs and one in liver; present further in vivo HSC data; present in vivo data in one liver indication; establish one additional target cell type/tissue; and continue to derive revenue through sublicensing foundational IP Strategic priorities through 2027 include: su

      1/13/25 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      CAMBRIDGE, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading gene editing company, today announced that the Company's President and CEO Gilmore O'Neill, M.B., M.M.Sc., will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, 11:15 a.m. PT / 2:15 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the "Investors" section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation. About Editas MedicineAs a leading gene editing company, Editas Medicine is focused on translating

      1/6/25 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

      Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel after extensive search did not yield a commercial partner The Company will work closely with the clinical trial sites, regulators, and other parties to determine the path forward for patien

      12/12/24 4:00:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

      Poster presentation at ASH on Monday, December 9 at 6:00 p.m. PT / 9:00 p.m. ET CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading gene editing company, will present updated safety and efficacy data in 28 patients living with severe sickle cell disease (SCD) treated with renizgamglogene autogedtemcel (reni-cel; formerly known as EDIT-301) in the Phase 1/2/3 RUBY clinical trial. The data will be presented by Dr. Rabi Hanna, M.D., Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, Cleveland Clinic Children's, during a poster presentation at the American Society of Hematology (ASH) Annual Meeting in San Diego, CA,

      12/9/24 12:00:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim's Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside ChatDate: Tuesday, December 3Time: 1:20 p.m. ETLocation: Coral Gables, FL To access the live webcasts of Editas Medicine

      11/6/24 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

      CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into

      9/25/23 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

      Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

      8/28/23 7:00:57 AM ET
      $EDIT
      $MDNA
      $TNGX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

      CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo

      7/24/23 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

      CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) --  Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Erick J. Lucera as Executive Vice President and Chief Financial Officer, effective May 17, 2023. Mr. Lucera will succeed Michelle Robertson, who has served in the role since January 2020 and is stepping down to pursue external opportunities. Ms. Robertson will remain with the Company in an advisory role through August 16, 2023, to ensure a smooth transition. "We are thrilled to welcome Erick to the executive leadership team as our new CFO. Erick brings to Editas a proven track record of driving financial decision-making, as

      5/16/23 4:30:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director

      Emma Reeve to support Editas' evolution in new role as Chair of the Board Elliott Levy, M.D., joins Board as an Independent Director CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical stage genome editing company, today announced the appointment of current Independent Director Emma Reeve as Chair of the Board, effective at the Company's next annual stockholder meeting, currently scheduled for June 1. Ms. Reeve will be replacing James C. Mullen as he steps down from the Board and his role as Executive Chair. The Company also announced the appointment of Elliott Levy, M.D., to its Board of Directors as an independent director.

      4/13/23 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

      CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linea Aspesi as the Company's Executive Vice President and Chief People Officer. Ms. Aspesi will lead Editas' human resources department and the Company's people strategy in support of its mission and goals. "Our people and our culture are critical ingredients for the success of our new strategy, and we are fortunate to have someone of Linea's caliber and expertise in defining, shaping, and implementing talent strategies for accelerated company growth. I look forward to working with Linea and the Leadership Team to help drive

      3/8/23 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

      CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Baisong Mei, M.D., Ph.D., as the Company's Senior Vice President and Chief Medical Officer, effective immediately. Dr. Mei will lead clinical research and drug development for the Company's pipeline of experimental medicines across all therapeutic indications, including hematology, oncology, and ophthalmology. "We are thrilled to have Baisong join our team. He brings to Editas a proven track record of advancing innovative medicines from IND acceptance through global regulatory approval. His extensive drug development experience and d

      7/18/22 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Appoints Gilmore O'Neill as Chief Executive Officer

      James C. Mullen to Serve as Executive Chairman CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that its Board of Directors has appointed Dr. Gilmore O'Neill, M.B., M.M.Sc., as President and Chief Executive Officer. James C. Mullen will serve as Executive Chairman of the Company's Board of Directors. These changes are effective June 1, 2022. Dr. O'Neill brings to Editas nearly 20 years of experience in genetic medicine, neurobiology, and clinical development. Dr. O'Neill also has a track record of driving and leading several of biotech's most successful clinical programs and achieving marketing app

      4/14/22 7:30:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dr. Jessica Hopfield Appointed to Berkeley Lights Board of Directors

      EMERYVILLE, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced the appointment of Jessica Hopfield, Ph.D. to the Berkeley Lights' Board of Directors as an independent director, effective December 15, 2021. "Dr. Hopfield is a respected and accomplished industry veteran, and we are thrilled to welcome her to our Board," said Eric Hobbs, Ph.D., chief executive officer of Berkeley Lights. "With more than two decades of medical device, biotech and pharmaceutical experience, Dr. Hopfield brings to Berkeley Lights valuable strategic insight and a strong focus on performance to drive our unrivaled ability to understand c

      12/20/21 8:32:00 AM ET
      $BLI
      $EDIT
      $MRVI
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations
    • Editas Medicine Names Bernadette Connaughton to Board of Directors

      CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its Board of Directors. Ms. Connaughton is an accomplished pharmaceutical executive with more than 30 years of global strategic, commercial, and biopharmaceutical industry expertise. Ms. Connaughton spent her career at Bristol-Myers Squibb, building a consistent track record of achieving sales growth, improving operational models, and increasing profitability in the U.S., Europe, and Asia. She most recently served as President, Intercontinental. In this role, she developed successful, multi-year commercia

      10/28/21 9:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. Financials

    Live finance-specific insights

    See more
    • Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

      On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional target cell type/tissue by year-endStrong cash position with operational runway into the second quarter of 2027 CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2024 and provided business upd

      3/5/25 4:05:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

      Focus on in vivo CRISPR-edited medicines based on Editas researchers' recent scientific progress in multiple tissues: Achieved pre-clinical in vivo proof of concept of high level HBG1/2 promoter editing and HbF induction in a humanized mouse model for treatment of sickle cell disease and beta thalassemia with a single dose of an HSC-targeted lipid nanoparticle (tLNP) formulationAchieved in vivo proof of concept of high efficiency editing in the liver in non-human primates Ending development of reni-cel after extensive search did not yield a commercial partner The Company will work closely with the clinical trial sites, regulators, and other parties to determine the path forward for patien

      12/12/24 4:00:00 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Third Quarter 2024 Results and Business Updates

      Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI

      11/4/24 7:30:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

      Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine's proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic

      10/22/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Second Quarter 2024 Results and Business Updates

      On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are hig

      8/7/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

      CAMBRIDGE, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, August 7, 2024, at 8:00 a.m. ET to discuss results for the second quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-800-343-4849 and international callers should dial +1-203-518-9848 approximately five minutes before the call begins.Participants should ask to be connected to the Editas Medicine Earnings Conference Call. The conference call will also be webcast and can be accessed from the "Investors" section of the Editas Medici

      7/31/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces First Quarter 2024 Results and Business Updates

      Completed adult cohort enrollment and enrolled multiple patients in the adolescent cohort of the Phase 1/2/3 RUBY clinical trial of reni-cel for severe sickle cell disease On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel for transfusion-dependent beta-thalassemia in mid-2024 and additional updates by year-end 2024 Presenting pre-clinical data at ASGCT on in vivo capabilities to support development of transformative in vivo gene editing medicines Strong financial position with operational runway into 2026 CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today r

      5/8/24 7:00:00 AM ET
      $BMY
      $EDIT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

      CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Participants should ask to be connected to the Editas Medicine Earnings Conference Call. The conference call will also be webcast and can be accessed from the "Investors" section of the Editas Medicine we

      5/2/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

      Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates by year-end 2024 Initiated enrollment in the adolescent cohort in the RUBY trial Entered into a license agreement providing Vertex Pharmaceuticals a non-exclusive license for Cas9 Strong financial position with operational runway expected into 2026 CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today reported financial results for the fourth quarter and full year 2023 and provided business updates. "I am pr

      2/28/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

      CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, February 28, 2024, at 8:00 a.m. ET to discuss results for the fourth quarter and full year 2023 and to provide a corporate update. To access the conference call: U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.Participants should ask to be connected to the Editas Medicine Earnings Conference Call. The conference call will also be webcast and can be accessed from the "Investors" section o

      2/21/24 7:00:00 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Editas Medicine Inc. SEC Filings

    See more
    • SEC Form DEFA14A filed by Editas Medicine Inc.

      DEFA14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:17:58 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Editas Medicine Inc.

      DEF 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/15/25 4:16:31 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by Editas Medicine Inc.

      PRE 14A - Editas Medicine, Inc. (0001650664) (Filer)

      4/4/25 4:38:47 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Editas Medicine Inc.

      EFFECT - Editas Medicine, Inc. (0001650664) (Filer)

      3/24/25 12:15:07 AM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Inc. filed SEC Form 8-K: Leadership Update

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      3/20/25 4:30:56 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POS AM filed by Editas Medicine Inc.

      POS AM - Editas Medicine, Inc. (0001650664) (Filer)

      3/5/25 5:10:50 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Editas Medicine Inc.

      S-8 - Editas Medicine, Inc. (0001650664) (Filer)

      3/5/25 4:40:42 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Editas Medicine Inc.

      10-K - Editas Medicine, Inc. (0001650664) (Filer)

      3/5/25 4:21:12 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Editas Medicine, Inc. (0001650664) (Filer)

      3/5/25 4:11:26 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form POSASR filed by Editas Medicine Inc.

      POSASR - Editas Medicine, Inc. (0001650664) (Filer)

      3/5/25 4:06:44 PM ET
      $EDIT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care